Augmented reality-based imaging company Augmedics announced that it raised $36 million in an oversubscribed Series C financing round. Having closed a $21 million Series B round eight months ago, Chicago-based Augmedics has raised $63 million to date, according to a news release. The company plans to use the funds to continue commercialization efforts, develop the […]
augmedics
20 medical device startups you need to know
The medtech industry isn’t immune from COVID-19 troubles, but exciting innovation continues. These 20 medical device startups have grabbed our attention. Tom Salemi, DeviceTalks Editorial Director and Sean Whooley, Assistant Editor A number of medical device startups continue to make waves across the space, with new technologies and eye-watering fundraising rounds highlighting some exciting prospects. […]
Augmedics launches its Xvision Spine AR nav system in U.S.
Augmedics announced today that it won FDA 510(k) clearance for and initiated the U.S. launch of its Xvision Spine augmented reality guidance system to be used in surgery. The company is touting Xvision Spine as the first AR guidance system to be used in surgery. The system is designed to allow surgeons to visualize the […]
Augmedics launches first-in-human Xvision-spine AR nav system trial
Surgical VR developer Augmedics said last week it began the first-in-human clinical trial of its Xvision-spine augmented reality surgical navigation center. The trial was launched at at Israel’s Sheba Tel Hashomer Medical Center and Asaf Harofeh Medical Center, led by co-principal investigators Dr. Ran Harel and Dr. Yigal Mirovsky. The Xvision-spine system is an AR surgical navigation […]
Surgical VR dev Augmedics raises $8m in Series A
Surgical VR developer Augmedics said today it raised $8.3 million in a Series A funding round to support its ViZOR system. The round was led by Davos, AO Invest, the Israeli Innovation Authority, Terra Venture Partners and other undisclosed investors, the Israel-based company said. Proceeds from the round will support continued R&D, pre-clinical trials of […]
